[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06839469":3,"trial-entities:NCT06839469":167,"trial-summary:NCT06839469":172},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":20,"study_type":34,"primary_purpose":35,"phases":36,"enrollment_info":37,"interventions":40,"primary_outcomes":41,"secondary_outcomes":67,"sex":81,"minimum_age":82,"maximum_age":35,"healthy_volunteers":83,"eligibility_criteria":84,"std_ages":95,"locations":99,"central_contacts":160,"overall_officials":164,"references":165,"see_also_links":166},"NCT06839469","AAAU9807","Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders","RECRUITING","2028-04-01","2026-04","2026-04-09","2024-05-01","Columbia University","OTHER",false,"The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.","Spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD) are genetic disorders that often result in progressive weakness and impaired function. Our recent findings suggest that novel machine-learning (ML)-based abstraction models may map noisy signals from foot-worn sensors (namely, instrumented insoles developed by the project team) into accurate and clinically relevant spatiotemporal and kinetic gait parameters. These gait parameters derived from instrumented insoles may serve as functional biomarkers to detect changes in real world function. All participants will be observed and measured while wearing the instrumented insoles in the lab and in real-life environments.",[18,19],"Spinal Muscular Atrophy Type 3","Duchenne Muscular Dystrophy (DMD)",[21,22,23,24,25,26,27,28,29,30,31,32,33],"SMA","spinal muscular atrophy","duchenne muscular dystrophy","DMD","instrumented insole","neuromuscular disease","machine learning model","gait analysis","functional biomarker","wearable","six minute walk test","ambulatory","becker phenotype","OBSERVATIONAL",null,[],{"count":38,"type":39},106,"ESTIMATED",[],[42,46,49,52,55,58,61,64],{"measure":43,"description":44,"timeFrame":45},"Six Minute Walk Test","Participants will complete the six minute walk test in a corridor which includes the instrumented walkway, while wearing the insoles. This is to measure spatial parameters, kinetic parameters, temporal parameters, and metrics of cumulative activity in order to compare against the gold standard instrumented walkway. The six minute walk test is an objective evaluation of functional exercise capacity, and measures the maximum distance a person can walk in six minutes over a 25 meter course.","One day",{"measure":47,"description":48,"timeFrame":45},"10 Meter Walk\u002FRun","Participants will walk, or run if able to, for 10 meters on the instrumented walkway while also wearing the insoles. This will be done to measure spatial parameters, kinetic parameters, temporal parameters, and metrics of cumulative activity in order to compare against the gold standard instrumented walkway. This outcome is reported as the time it takes for the participant to complete 10 meters as fast as possible.",{"measure":50,"description":51,"timeFrame":45},"Time Up and Go Test (TUG)","Participants will complete the TUG test. This is a timed test of mobility, requiring the participant to stand up from a seated position, walk 3 meters and return to sitting in the chair. The outcome reported is the time it takes for the participant to complete the sequence.",{"measure":53,"description":54,"timeFrame":45},"Muscle Strength Testing with Hand-held Dynamometry (HHD)","HHD is used to assess the strength of muscles and is reported as the maximum strength exerted in pounds (lbs).",{"measure":56,"description":57,"timeFrame":45},"30 Second Sit to Stand Test (30STS)","30STS test is used to basic muscle power and function. The participant begins seated with their arms at their sides, feet flat on the floor and back against the chair. They are instructed to rise up to a full standing position and sit back down as many times as possible in 30 seconds, with or without using their hands for support.",{"measure":59,"description":60,"timeFrame":45},"Ankle Range of Motion","Ankle range of motion (ROM) will be assessed on both the left right side using standardized goniometers. The procedures used will be standardized and performed by trained physical therapists who have attended in-person training. ROM will be recorded in degrees for plantar flexion and dorsiflexion.",{"measure":62,"description":63,"timeFrame":45},"Knee Extension Range of Motion","Knee extension range of motion (ROM) will be assessed on both the left right side using standardized goniometers. The procedures used will be standardized and performed by trained physical therapists who have attended in-person training. ROM will be recorded in degrees of knee extension.",{"measure":65,"description":66,"timeFrame":45},"Hip Extension Range of Motion","Hip extension range of motion (ROM) will be assessed on both the left right side using standardized goniometers. The procedures used will be standardized and performed by trained physical therapists who have attended in-person training. ROM will be recorded in degrees of hip extension.",[68,72,75,78],{"measure":69,"description":70,"timeFrame":71},"Free-living Testing of Instrumented Insoles","To determine spatial parameters, kinetic parameters, temporal parameters, and metrics of cumulative activity using instrumented insoles, participants with SMA, DMD, and healthy controls will be asked to wear the insoles along with a validated activity tracker. Participants will be asked to wear the insoles during a single day visit to the lab, and then for at least 180 hours at home in a real-life environment. Participants will be asked to wear the insoles and activity tracker for at least 6 hours per day when at home. Compliance with this outcome will be measured in total hours the insoles are worn over the study period (one month).","One month",{"measure":73,"description":74,"timeFrame":71},"Validation of Physical Activity using Actigraph accelerometer","An Actigraph will be provided and worn during waking hours, while the participant is also wearing the insoles. Data extracted are counts per minutes, and are measurements of movement performed in both vertical and horizontal axis. The counts will be used to quantify the time the participant is inactive, low, moderate and \u002F or in vigorous physical active.",{"measure":76,"description":77,"timeFrame":45},"International Physical Activity Questionnaire-Short Form, IPAQ-SF","The IPAQ-SF is a self report questionnaire that assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives. It is used estimate total physical activity in MET-min\u002Fweek and time spent sitting in the 7 days prior to completing the questionnaire. It will be completed by participants aged 18 and over, at the start and at the end of the one-month insole wear time.",{"measure":79,"description":80,"timeFrame":45},"PROMIS Pediatric Physical Activity Questionnaire","The pediatric activity questionnaire measures a child's self-report of short bouts of moderate to vigorous physical activity. This questionnaire is designed to measure constructs best recalled by children such as physiological response, symptoms, and short bouts of higher intensity activity. The questionnaire has an 8-item bank and is intended for use with children ages 8 to 17 years or with a parent proxy version for children aged 5 to 17 years. It will be completed at the start and at the end of the one month insole wear time and scores will calculated and range from 8-40.","ALL","5 Years",true,{"inclusion":85,"exclusion":90,"raw_text":94},[86,87,88,89],"Genetic confirmation of disease (DMD, SMA) or healthy control","Able to walk independently at least 25 meters","Ongoing corticosteroids therapy or initiation of corticosteroid therapy in the previous 3 months for DMD","Stable dose of FDA approved SMN up-regulator therapy or in an open-label extension phase of a study treatment for at least 6 months for SMA or gene replacement at enrollment for SMA or DMD participants.",[91,92,93],"Use foot orthoses or assistive devices for community ambulation or a mobility device for community navigation","Use investigational medications intended for treatment of NMD within 30 days","Prior to study entry had an injury or surgery that would impact gait within the previous 3 months","Inclusion Criteria:\n\n* Genetic confirmation of disease (DMD, SMA) or healthy control\n* Able to walk independently at least 25 meters\n* Ongoing corticosteroids therapy or initiation of corticosteroid therapy in the previous 3 months for DMD\n* Stable dose of FDA approved SMN up-regulator therapy or in an open-label extension phase of a study treatment for at least 6 months for SMA or gene replacement at enrollment for SMA or DMD participants.\n\nExclusion Criteria:\n\n* Use foot orthoses or assistive devices for community ambulation or a mobility device for community navigation\n* Use investigational medications intended for treatment of NMD within 30 days\n* Prior to study entry had an injury or surgery that would impact gait within the previous 3 months",[96,97,98],"CHILD","ADULT","OLDER_ADULT",[100,124,144],{"facility":101,"status":7,"city":102,"state":103,"zip":104,"country":105,"contacts":106,"geoPoint":121},"Stanford University","Palo Alto","California","94304","United States",[107,112,116,119],{"name":108,"role":109,"phone":110,"email":111},"Sally Dunaway Young, PT, DPT","CONTACT","650-497-0075","sdy@stanford.edu",{"name":113,"role":109,"phone":114,"email":115},"Constance De Monts, PT, DPT","6502502292","cdemonts@stanford.edu",{"name":117,"role":118},"John W Day, MD","PRINCIPAL_INVESTIGATOR",{"name":108,"role":120},"SUB_INVESTIGATOR",{"lat":122,"lon":123},37.44188,-122.14302,{"facility":125,"status":7,"city":126,"state":127,"zip":128,"country":105,"contacts":129,"geoPoint":141},"Boston Children's Hospital","Boston","Massachusetts","02115",[130,134,138,139],{"name":131,"role":109,"phone":132,"email":133},"Amy Pasternak, PT, DPT","617-355-7212","amy.pasternak@childrens.harvard.edu",{"name":135,"role":109,"phone":136,"email":137},"Maria Fragala Pinkham, PT, DPT, DSc","6173557212","maria.pinkham@childrens.harvard.edu",{"name":131,"role":118},{"name":140,"role":120},"Maria F Fragala Pinkham, PT, DPT, Dsc",{"lat":142,"lon":143},42.35843,-71.05977,{"facility":145,"status":7,"city":146,"state":146,"zip":147,"country":105,"contacts":148,"geoPoint":157},"Columbia University Irving Medical Center","New York","10032",[149,153],{"name":150,"role":109,"phone":151,"email":152},"Jacqueline Montes","212-305-8916","jm598@cumc.columbia.edu",{"name":154,"role":109,"phone":155,"email":156},"Cara Kanner, DPT","516-581-8150","chy2112@cumc.columbia.edu",{"lat":158,"lon":159},40.71427,-74.00597,[161,163],{"name":162,"role":109,"phone":151,"email":152},"Jacqueline Montes, PT, EdD",{"name":154,"role":109,"phone":155,"email":156},[],[],[],{"nct_id":4,"conditions":168,"biomarkers":171},[169,170],"Duchenne Muscular Dystrophy","Spinal Muscular Atrophy",[],{"nct_id":4,"found":83,"summary":173,"prompt_version":183},{"design":174,"status":175,"heading":176,"summary":177,"follow_up":178,"word_count":179,"commitments":180,"compensation":181,"drugs_mentioned":182},"This is an observational study with a planned enrollment of 106 participants. It is not a drug trial, but rather aims to understand disease progression through walking patterns.","completed","Walking-related Digital Biomarkers in Childhood Neuromuscular Disorders","This observational study aims to understand how walking patterns, measured by special insoles, can show changes in Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy Type 3 (SMA Type 3). Researchers want to find digital biomarkers (measurable indicators) that show how severe the disease is and how it changes over time in everyday life. You might be able to join if you have a confirmed diagnosis of DMD or SMA, or are a healthy control, and can walk independently for at least 25 meters. For DMD, you need to be on corticosteroids or have started them recently. For SMA, you need to be on a stable dose of an FDA-approved SMN up-regulator therapy or in an open-label extension for at least 6 months. The study will measure walking ability using tests like the Six Minute Walk Test, 10 Meter Walk\u002FRun, and Time Up and Go Test. The current recruitment status is unclear.","Walking tests are measured on one day. The study aims to monitor longitudinal changes, but specific follow-up duration is not detailed.",152,"Participants will wear instrumented insoles in a lab setting and in their daily lives. Walking tests like the Six Minute Walk Test will be performed on one day.","Not stated in the trial record.",[],"v2"]